Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Daily5d
Sanofi gets USFDA Breakthrough Therapy designation for multiple sclerosis therapy Tolebrutinib
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Multiple Sclerosis News Today5d
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
PMLiVE5d
Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS
Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy ...
Pharmabiz6d
Sanofi’s tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis receives US FDA breakthrough therapy designation
Sanofi’s tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis receives US FDA breakthrough therapy designation: Paris Monday, December 16, 2024, 12:00 Hr ...
Sanofi: Promising Growth with Strategic Developments and Robust Pipeline
Analyst Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report) and keeping the price target ...
pharmaphorum4d
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...
pharmaphorum1d
Two of three trials fail, but Sanofi will still file MS drug
Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...